A novel drug delivery using a dissolvable microneedle array that would both treat – and potentially prevent the recurrence of – basal cell and squamous cell skin cancer. SkinJect will offer an effective way to eliminate existing non-melanoma skin cancers while potentially preventing recurrence as well as providing a safe, convenient way to deliver therapy.

Sector: Drug Delivery

Year Funded: 2016

Signalence logo

Signalence develops innovative solutions to “signal” detection. These signals can range from signs of illicit covert communication to signs or symptoms of disease. Our inventions are designed to capture signals, interpret their meaning, and help the user take the necessary steps to address the “signs” of a problem.

Periovance | Under development